No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GRAL240816P17500
- 2.50
- +0.30+13.64%
15min DelayClose Jul 19 15:59 ET
2.50High2.00Low
2.00Open2.20Pre Close3 Volume32 Open Interest17.50Strike Price660.00Turnover85.05%IV9.53%PremiumAug 16, 2024Expiry Date0.92Intrinsic Value100Multiplier25DDays to Expiry1.58Extrinsic Value100Contract SizeAmericanOptions Type-0.5449Delta0.1063Gamma8.29Leverage Ratio-0.0277Theta-0.0068Rho-4.52Eff Leverage0.0175Vega
Intraday
- 5D
- Daily
News
The Race to Develop the 'Holy Grail' of Weight-loss Drugs
Stock Warnings: Sunpower, Domino's, and Grail
Grail Announces First Patients Enrolled in REACH Cancer Trial
Express News | GRAIL Shares Are Trading Lower. The Company Announced That the First Participant Has Been Enrolled in the REACH/Galleri-Medicare Study at Community Health Network
Express News | Grail Inc - Medicare to Cover Costs for Galleri Study Participants
Express News | Grail Announces First Participant Enrolled in Reach Study Evaluating Clinical Impact of Galleri® Multi-Cancer Early Detection (Mced) Test in the Medicare Population
Comments
$Grail(GRAL.US$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
1
$Illumina(ILMN.US$ botched the acquisition of $Grail(GRAL.US$ after the move was banned by european authorities and has finished divesting as GRAL just opened shop on stock markets very recently as a separate entity from ILMN. with this shareholders might start to pour money back into Illumina which is clearly undervalued by any metric you throw at it it's not a dead business so there's some money to be made here you can look at the chart recently ...
5
$Grail(GRAL.US$ why circuit breaker?
Read more